Key result
A model including VKORC1 and CYP2C9 genotypes, age, sex, and body weight accounted for 61% of the variance in warfarin daily maintenance dose.
Why the study?
Do VKORC1 and CYP2C9 genotypes explain the variance in warfarin maintenance dose requirements in patients on stable anticoagulation?
Population
65 patients with stable anticoagulation
Comparison
VKORC1 (-1639 G>A) and CYP2C9 genotyping vs Comparison across different VKORC1 and CYP2C9…
Design
Cross-sectional
Authors
Loading...
Supports genotype-inclusive warfarin dosing models; leaves open whether testing improves outcomes before clinical adoption.
Observational (n=65)
Do VKORC1 and CYP2C9 genotypes explain the variance in warfarin maintenance dose requirements in patients on stable anticoagulation?
Effect estimate: 61% variance explained
VKORC1 and CYP2C9 genotypes, combined with clinical factors, account for the majority of variance in warfarin maintenance dose requirements.
Zhu et al. (2007) conducted an observational in Stable anticoagulation (n=65). VKORC1 and CYP2C9 genotyping vs. Different VKORC1 and CYP2C9 genotypes was evaluated on Variance in warfarin daily maintenance dose (61% variance explained). A model including VKORC1 and CYP2C9 genotypes, age, sex, and body weight accounted for 61% of the variance in warfarin daily maintenance dose.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: